Maze Therapeutics Files Q1 2025 10-Q
Ticker: MAZE · Form: 10-Q · Filed: May 14, 2025 · CIK: 1842295
| Field | Detail |
|---|---|
| Company | Maze Therapeutics, Inc. (MAZE) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, licensing-agreement, preferred-stock
TL;DR
Maze Therapeutics Q1 10-Q is in. Stockholder equity and license deals detailed.
AI Summary
Maze Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including details on its Series C and Series D1 Redeemable Convertible Preferred Stock. The filing also references license agreements with Shionogi and Neurocrine, with potential milestone payments.
Why It Matters
This filing provides investors with an update on Maze Therapeutics' financial health and ongoing business activities, including key licensing deals that could impact future revenue.
Risk Assessment
Risk Level: medium — The company is in the biotechnology sector, which is inherently risky due to long development cycles and regulatory hurdles.
Key Numbers
- N/A — Revenue (Specific revenue figures are not readily available in the provided snippet.)
- N/A — Net Income (Specific net income figures are not readily available in the provided snippet.)
Key Players & Entities
- Maze Therapeutics, Inc. (company) — Filer of the 10-Q
- Shionogi (company) — Party to a license agreement
- Neurocrine (company) — Party to a license agreement
- 2025-03-31 (date) — End of reporting period
FAQ
What is the total value of the Series C Redeemable Convertible Preferred Stock as of March 31, 2025?
The filing indicates Series C Redeemable Convertible Preferred Stock was present as of 2024-01-01 to 2024-03-31, but a specific total value for March 31, 2025, is not detailed in this snippet.
Are there any upcoming milestone payments related to the Shionogi license agreement?
The filing mentions the Shionogi License Agreement and potential milestone payments, but specific upcoming payment details are not provided in this snippet.
What was the fair value measurement level for assets as of December 31, 2024?
The filing indicates 'us-gaap:FairValueInputsLevel1Member' and 'us-gaap:FairValueMeasurementsRecurringMember' were relevant as of 2024-12-31, suggesting Level 1 inputs were used for recurring fair value measurements.
What is the context for 'srt:MaximumMember' in relation to 'us-gaap:OtherCurrentAssetsMember' on March 31, 2025?
The filing shows 'us-gaap:OtherCurrentAssetsMember' and 'srt:MaximumMember' as of 2025-03-31, implying that the reported other current assets represent the maximum value or a key metric within that category.
When was the Neurocrine License Agreement active during the reporting period?
The Neurocrine License Agreement is referenced with activity between 2024-05-01 and 2024-05-31, and again between 2024-05-01 and 2024-05-31, indicating its relevance during that timeframe.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding Maze Therapeutics, Inc. (MAZE).